Cite
HARVARD Citation
Guo, X. et al. (n.d.). 167P TisCRT-LAPC: A phase Ⅱ clinical trial of tislelizumab plus chemotherapy (nab-paclitaxel and gemcitabine, AG) followed by consolidative radiotherapy in locally advanced pancreatic cancer (LAPC). Immuno-oncology technology. p. . [Online].